References
- DaPrada M, Zurcher G, Wuthricht I, Haefely W. On tyramine, food, beverages, and the reversible MAO inhibitor moclobemide. J Neural Transm 1988; 26(suppl)31–56
- Golbe L I. Deprenyl as symptomatic therapy in parkinson's disease. Clin Neuropharmacol 1988; 11(5)387–400
- Heinonen E H, Rinne U K. Selegiline in the treatment of parkinson's disease. Acta Neurol Scand 1989; 126: 103–111
- Bodkin J A, Amsterdam J D. Transdermal selegiline in major depression: a double‐blind, placebo‐controlled, parallel‐group study in outpatients. Am J Psychiatry 2002; 159(11)1869–1875
- Amsterdam J D. A double‐blind, placebo‐controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003; 64(2)208–214
- Mann J J, Aarons S F, Wilner P J, Keilp J G, Sweeney J A, Pearlstein T, Frances A J, Kocsis J H, Brown R P. A controlled study of the antidepressant efficacy and side effects of (−)‐deprenyl: a selective monoamine oxidase inhibitor. Arch Gens Psychiatry 1989; 46(1)45–50
- McGrath P J, Stewart J W, Harrison W, Wager S, Nunes E N, Quitkin F M. A placebo‐controlled trial of l‐deprenyl in atypical depression. Psychopharmacol Bull 1989; 25(1)63–67
- Sunderland T, Cohen R M, Molchan S, Lawlor B A, Mellow A M, Newhouse P A, Tariot P N, Mueller E A, Murphy D L. High‐dose selegiline in treatment‐resistant older depressive patients. Arch Gen Psychiatry 1994; 51(8)607–615
- Mawhinney M, Cole D, Azzaro A J. Daily transdermal administration of selegiline to guinea pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol 2003; 55(1)27–34
- Wecker L, Goodhead M L, Azzaro A J, Pacheco M A. The Selegiline Transdermal System (STS): Targeted Effects on Monoamine Oxidases in the Brain. Presented at: American College of Neuropsychopharmacology Annual Meeting, San JuanPuerto Rico, December, 2000
- Pauporte M, Maibach H I, Goodhead M, Azzaro A J, Moonsammy G. Selegiline transdermal system (STS): preclinical assays of dermal safety. J Toxicol Cutaneous Ocular Toxicol 200X; x(x)xx
- Data on File. Somerset Pharmaceuticals, Inc., Tampa, FL
- Marzulli F, Maibach H I. Test Methods for Allergic Contact Dermatitis in Humans. Dermatotoxicology5th Ed, F N Marzulli, H I Maibach. Taylor and Frances, New York 1996; 477–484
- Mitchell J, Maibach H. Managing the excited skin syndrome: patch testing hyperirritable skin. Contact Dermatitis 1997; 37(5)193–199
- Physicians' Desk Reference53rd ed. Thomson Healthcare, Montvale, NJ 1999; 1535–1538
- Patil S, Hogan D, Maibach H I. Transdermal drug delivery systems. Dermatotoxicology5th ed, F Marzulli, H I Maibach. Taylor and Frances, New York 1996; 389–396